Study 181-1-06-01 - phase 1A clinical study with DAS181: Double-blind, randomized, placebo-controlled, single dose escalating study in healthy adults
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2015
At a glance
- Drugs DAS 181 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors NexBio
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2009 The study was completed in Dec 2008 and the drug was well tolerated at all dosage levels, according to a NexBio media release.
- 06 Jan 2009 Planned number of patients changed from 60 to 36 as reported by ClinicalTrials.gov.